Analysis, sample size, and power for estimating incremental net health benefit from clinical trial data

Controlled Clinical Trials

Volumn 22, Issue 3, 2001, Pages 228-237

  Willan, Andrew R ^a,b  

^a MCMASTER UNIVERSITY   (Canada)

^b CENTRE FOR EVALUATION OF MEDICINES   (Canada)

Author keywords

Analysis; Cost effectiveness analysis; Incremental cost effectiveness ratios; Net health benefits; Power; Randomized clinical trials; Sample size

Indexed keywords

ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; COST BENEFIT ANALYSIS; COST EFFECTIVENESS ANALYSIS; HEALTH CARE COST; HEALTH INSURANCE; MATHEMATICAL COMPUTING; RANDOMIZED CONTROLLED TRIAL; SAMPLE; STATISTICAL ANALYSIS; VARIANCE;

BIOMETRY; COST-BENEFIT ANALYSIS; HUMANS; MALE; PROSTATIC NEOPLASMS; QUALITY-ADJUSTED LIFE YEARS; RANDOMIZED CONTROLLED TRIALS; SAMPLE SIZE;

EID: 0034994363     PISSN: 01972456     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0197-2456(01)00110-6     Document Type: Article

References (32)

1. Users' guides to the medical literature. XIII How to use an article on economic analysis of clinical practice part A: Are the results of the study valid?
2. Users' guides to the medical literature XIII. How to use an article on economic analysis of clinical practice part B: What are the results and will they help me in caring for my patients?
3. In search of power and significance: Issues in the design and analysis of stochastic cost-effectiveness studies in heath care
4. Confidence intervals for cost-effectiveness ratios: An application of Fieller's theorem
5. Confidence intervals for cost-effectiveness ratios: An example from a randomized trial
6. Statistical issues of cost-effectiveness analysis
7. What you don't know can't hurt you? Statistical issues and standards for medical technology evaluation
8. Reflecting uncertainty in cost effectiveness analysis
9. Pulling cost-effectiveness analysis up by its bootstraps; a non-parametric approach to confidence interval estimation
10. Costs effects and C/E ratios alongside a clinical trial
11. Confidence intervals for cost/effectiveness ratios
12. Confidence intervals for cost-effectiveness ratios: A comparison of four methods
13. Net health benefits: A new framework for the analysis of uncertainty in cost-effectiveness analysis
14. On the (near) equivalence of cost-effectiveness and cost-benefit analysis
15. The interpretation of results of economic evaluation: Explicating the value of health
16. A note on confidence intervals in cost-effectiveness analysis
17. Incremental net benefit in randomized clinical trials
18. Sample size calculations in economic evaluations
19. Power and sample size calculations for stochastic cost-effectiveness analysis
20. Sample size and power issues in estimating incremental cost-effectiveness ratios from clinical trials data
21. An economic approach to clinical design and research priority setting
22. The irrelevance of inference: A decision-making approach to the stochastic evaluation of health care technologies
23. Bayesian approaches to the value of information: Implications for the regulation of new pharmaceuticals
24. Chemotherapy with mitoxantrone plus prednisone or prednisone alone for symptomatic hormone-resistant prostate cancer: A Canadian trial with palliative endpoints
25. Economic evaluation of chemotherapy with mitoxantrone plus prednisone for symptomatic hormone-resistant prostate cancer: Based on a Canadian trial with palliative endpoints
26. How attractive does a new technology have to be to warrant adoption and utilisation? Tentative guidelines for using clinical and economic evaluations
27. Handling uncertainty when performing economic evaluation of health care interventions
28. Confidence intervals or surfaces? Uncertainty on the cost-effectiveness plane
29. A Bayesian approach to stochastic cost-effectiveness analysis
30. Cost effectiveness analysis of improved blood pressure control in hypertensive patients with type 2 diabetes: UKPDS 40
31. Bayesian cost effectiveness analysis from clinical trial data